Black Diamond Therapeutics AI Stock Analysis
Want to see BDTX full AI Analyst Report?
Black Diamond Therapeutics (BDTX) AI Stock Analysis
Black Diamond Therapeutics
(NASDAQ:BDTX)
The score is weighed down primarily by inconsistent financial performance and ongoing TTM losses/cash burn despite a stronger low-debt balance sheet, alongside weak technical signals with the price below major moving averages and negative MACD. Valuation is also challenged by a negative P/E and no dividend yield data to offset risk.
Black Diamond Therapeutics (BDTX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $84.48M
- Dividend Yield
- ―
- Average Volume (3M)
- 703.96K
- Price to Earnings (P/E)
- -1.9
- Beta (1Y)
- 2.08
- Revenue Growth
- -100.00%
- EPS Growth
- -302.37%
- Country
- US
- Employees
- 21
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Black Diamond Therapeutics Business Overview & Revenue Model
Company Description
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDT...
How the Company Makes Money
BDTX is a clinical-stage biotechnology company and, as such, it generally does not generate recurring commercial product revenue unless it has an approved product (null). Its funding and revenue sources typically come from (i) collaboration and licen...
Black Diamond Therapeutics Financial Statement Overview
Summary
Balance sheet is a relative strength with low leverage and positive equity (TTM equity ~$88.1M; debt-to-equity ~0.18). However, operating results and cash flows are unstable: profitability in 2025 (net income $22.4M; positive FCF $29.6M) contrasts with the most recent TTM net loss (-$44.1M) and negative free cash flow (-$33.3M), indicating uncertain revenue durability and ongoing burn.
Income Statement
28NegativeBalance Sheet
62PositiveCash Flow
34Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 70.00M | 0 | 0 | 0 | 0 |
| Gross Profit | -55.00K | 69.67M | 0 | -437.00K | 0 | 0 |
| EBITDA | -44.59M | 22.69M | -69.33M | -82.00M | -90.66M | -125.39M |
| Net Income | -44.07M | 22.37M | -69.68M | -82.44M | -91.17M | -125.60M |
Balance Sheet | ||||||
| Total Assets | 115.56M | 143.01M | 122.64M | 158.57M | 156.25M | 247.68M |
| Cash, Cash Equivalents and Short-Term Investments | 102.03M | 128.65M | 98.58M | 131.40M | 122.81M | 209.79M |
| Total Debt | 16.04M | 18.78M | 22.19M | 25.30M | 28.14M | 28.46M |
| Total Liabilities | 27.48M | 30.80M | 39.35M | 41.83M | 40.56M | 51.78M |
| Stockholders Equity | 88.08M | 112.21M | 83.28M | 116.74M | 115.69M | 195.90M |
Cash Flow | ||||||
| Free Cash Flow | -32.50M | 29.61M | -62.30M | -66.75M | -85.27M | -102.86M |
| Operating Cash Flow | -32.50M | 29.61M | -62.30M | -66.72M | -85.08M | -100.15M |
| Investing Cash Flow | 17.70M | -44.91M | 16.97M | 16.35M | 53.37M | 130.61M |
| Financing Cash Flow | -152.00K | -146.00K | 25.55M | 71.93M | 177.00K | 729.00K |
Black Diamond Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDTX, the sentiment is Negative. The current price of 1.47 is below the 20-day moving average (MA) of 1.79, below the 50-day MA of 1.85, and below the 200-day MA of 2.15, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 37.06 is Neutral, neither overbought nor oversold. The STOCH value of 4.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BDTX.
Black Diamond Therapeutics Risk Analysis
Black Diamond Therapeutics disclosed 81 risk factors in its most recent earnings report. Black Diamond Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksBlack Diamond Therapeutics Peers Comparison
Overall Rating
ONCY46Neutral
BDTX44Neutral
ADCT43Neutral
KZIA42Neutral
TCRX38.35Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | $47.18M | -1.32 | 664.95% | ― | ― | 11.90% | |
| 44Neutral | $84.48M | -1.93 | -43.99% | ― | -100.00% | -302.37% | |
| 43Neutral | $188.49M | -2.56 | 36.95% | ― | 12.85% | 63.71% | |
| 42Neutral | $75.65M | -0.94 | -116.86% | ― | -98.25% | 76.83% | |
| 38Underperform | $10.89M | -0.18 | -140.75% | ― | -38.43% | 20.89% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BDTX | Black Diamond Therapeutics, Inc. | 1.47 | -2.54 | -63.34% | |
| KZIA | Kazia Therapeutics Limited | 6.62 | 0.54 | 8.88% | |
| ONCY | Oncolytics Biotech | 0.37 | -0.68 | -64.76% | |
| ADCT | ADC Therapeutics Ltd | 1.34 | -2.63 | -66.25% | |
| TCRX | Tscan Therapeutics, Inc. | 0.16 | -0.81 | -83.51% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026
